SG11201808928YA - Cationic lipid - Google Patents
Cationic lipidInfo
- Publication number
- SG11201808928YA SG11201808928YA SG11201808928YA SG11201808928YA SG11201808928YA SG 11201808928Y A SG11201808928Y A SG 11201808928YA SG 11201808928Y A SG11201808928Y A SG 11201808928YA SG 11201808928Y A SG11201808928Y A SG 11201808928YA SG 11201808928Y A SG11201808928Y A SG 11201808928YA
- Authority
- SG
- Singapore
- Prior art keywords
- carbon atoms
- cationic lipid
- formulae
- formula
- independently represent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (a) or a pharmaceutically acceptable salt thereof. (In formula (la), each of L 1 and L2 independently represent an alkylene group having 3-10 carbon atoms; each of R 1 and R2 independently represent an alkyl group having 4-22 carbon atoms or an alkenyl group having 4-22 carbon atoms; X i represents a single bond or -CO-O-; and ring P represents one of formulae (P-1) to (P-5).)(In formulae (P-1) to (P-5), R3 represents an alkyl group having 1-3 carbon atoms.) 0 -0-- 0 R 1 ,... , .....---,, 0 L 1 X 1 L2 R ( 1 a) N\"R3 r -----N C\N-R3 H, R3 .\\) cN,,) \,.IsIN__/ \ ,- (PA) (P-2) (P-3) (P-4) (P-5) 123
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016125925 | 2016-06-24 | ||
PCT/JP2017/023051 WO2017222016A1 (en) | 2016-06-24 | 2017-06-22 | Cationic lipid |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808928YA true SG11201808928YA (en) | 2018-11-29 |
Family
ID=60784078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808928YA SG11201808928YA (en) | 2016-06-24 | 2017-06-22 | Cationic lipid |
Country Status (15)
Country | Link |
---|---|
US (1) | US10501416B2 (en) |
EP (1) | EP3476832B1 (en) |
JP (1) | JP6883034B2 (en) |
KR (1) | KR102358341B1 (en) |
CN (1) | CN109311809B (en) |
AU (1) | AU2017282459B2 (en) |
BR (1) | BR112018075123A2 (en) |
CA (1) | CA3020271A1 (en) |
ES (1) | ES2948971T3 (en) |
IL (1) | IL262574B (en) |
MX (1) | MX2018015236A (en) |
RU (1) | RU2740921C2 (en) |
SG (1) | SG11201808928YA (en) |
TW (1) | TWI745386B (en) |
WO (1) | WO2017222016A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7164547B2 (en) * | 2017-12-27 | 2022-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | cationic lipid |
CN110283223B (en) * | 2018-03-19 | 2022-01-04 | 广州市锐博生物科技有限公司 | Cationic lipid molecule and application thereof in nucleic acid delivery |
EP3842412B1 (en) * | 2018-08-21 | 2024-04-24 | Kabushiki Kaisha Toshiba | Biodegradable lipids for delivery of active compounds into tumor cells comprising two or more tertiary amino groups |
US10526603B1 (en) * | 2018-10-26 | 2020-01-07 | Eisai R&D Management Co., Ltd. | Double-stranded ribonucleic acid capable of suppressing expression of complement C5 |
JP6918197B2 (en) * | 2019-12-26 | 2021-08-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pharmaceutical composition containing lipid complex and pharmaceutical composition containing lipid nanoparticles |
AU2020413311A1 (en) * | 2019-12-26 | 2022-06-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5 |
US20240180954A1 (en) | 2021-02-04 | 2024-06-06 | Shionogi & Co., Ltd. | Cationic lipid |
EP4409002A1 (en) * | 2021-09-28 | 2024-08-07 | Seqirus Inc. | Ionizable cationic compound |
CN114874150A (en) * | 2022-02-22 | 2022-08-09 | 中国科学院基础医学与肿瘤研究所(筹) | Bivalent ionizable lipid compound, composition and application thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2350043T3 (en) | 2008-10-09 | 2014-09-30 | Tekmira Pharmaceuticals Corp | Improved amino lipids and methods for the delivery of nucleic acids |
PL3431076T3 (en) | 2009-06-10 | 2022-01-31 | Arbutus Biopharma Corporation | Improved lipid formulation |
KR20190039347A (en) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | Biodegradable lipids for the delivery of active agents |
KR101878361B1 (en) | 2010-09-20 | 2018-08-20 | 시르나 쎄러퓨틱스 인코퍼레이티드 | Novel low molecular weight cationic lipids for oligonucleotide delivery |
DK2635265T3 (en) | 2010-11-05 | 2018-07-16 | Sirna Therapeutics Inc | New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery |
AU2012325997C1 (en) | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
WO2013086354A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
CN104168887B (en) * | 2012-03-16 | 2018-09-04 | 默克专利股份有限公司 | amino acid lipids |
EP2838877B1 (en) | 2012-04-19 | 2018-09-12 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
TW201408625A (en) * | 2012-07-06 | 2014-03-01 | Kyowa Hakko Kirin Co Ltd | Cationic lipid |
CA2891911C (en) | 2012-12-07 | 2023-03-07 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
TW201534578A (en) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | Novel lipid |
US20160367638A1 (en) | 2013-12-19 | 2016-12-22 | Crystal BYERS | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
EP4019506A1 (en) * | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
CA2935914C (en) * | 2014-01-09 | 2022-02-08 | Eisai R&D Management Co., Ltd. | Cationic lipid |
CA2959358C (en) * | 2014-06-30 | 2022-07-26 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
EP3239132B1 (en) | 2014-12-26 | 2019-03-06 | Eisai R&D Management Co., Ltd. | Cationic lipid |
-
2017
- 2017-06-22 MX MX2018015236A patent/MX2018015236A/en unknown
- 2017-06-22 JP JP2018524158A patent/JP6883034B2/en active Active
- 2017-06-22 RU RU2018143237A patent/RU2740921C2/en active
- 2017-06-22 CA CA3020271A patent/CA3020271A1/en active Pending
- 2017-06-22 TW TW106120878A patent/TWI745386B/en active
- 2017-06-22 BR BR112018075123A patent/BR112018075123A2/en not_active Application Discontinuation
- 2017-06-22 CN CN201780035314.7A patent/CN109311809B/en active Active
- 2017-06-22 SG SG11201808928YA patent/SG11201808928YA/en unknown
- 2017-06-22 AU AU2017282459A patent/AU2017282459B2/en active Active
- 2017-06-22 EP EP17815482.9A patent/EP3476832B1/en active Active
- 2017-06-22 KR KR1020187034307A patent/KR102358341B1/en active IP Right Grant
- 2017-06-22 ES ES17815482T patent/ES2948971T3/en active Active
- 2017-06-22 US US16/307,202 patent/US10501416B2/en active Active
- 2017-06-22 WO PCT/JP2017/023051 patent/WO2017222016A1/en active Application Filing
-
2018
- 2018-10-24 IL IL262574A patent/IL262574B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3476832B1 (en) | 2023-04-19 |
WO2017222016A1 (en) | 2017-12-28 |
TWI745386B (en) | 2021-11-11 |
EP3476832A1 (en) | 2019-05-01 |
JPWO2017222016A1 (en) | 2019-04-18 |
KR20190021218A (en) | 2019-03-05 |
RU2018143237A3 (en) | 2020-07-24 |
KR102358341B1 (en) | 2022-02-07 |
US10501416B2 (en) | 2019-12-10 |
RU2018143237A (en) | 2020-07-24 |
EP3476832A4 (en) | 2020-02-19 |
ES2948971T3 (en) | 2023-09-22 |
US20190218180A1 (en) | 2019-07-18 |
TW201803849A (en) | 2018-02-01 |
JP6883034B2 (en) | 2021-06-02 |
MX2018015236A (en) | 2019-04-11 |
AU2017282459B2 (en) | 2021-05-06 |
RU2740921C2 (en) | 2021-01-21 |
AU2017282459A1 (en) | 2018-11-01 |
CN109311809A (en) | 2019-02-05 |
IL262574B (en) | 2021-10-31 |
CN109311809B (en) | 2022-04-08 |
CA3020271A1 (en) | 2017-12-28 |
IL262574A (en) | 2018-12-31 |
BR112018075123A2 (en) | 2019-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808928YA (en) | Cationic lipid | |
EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
TN2020000158A1 (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
MX2018011831A (en) | SOLUBLE C5aR ANTAGONISTS. | |
MX2020000268A (en) | Fxr receptor agonist. | |
TN2018000319A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
MX2020005363A (en) | Heterocyclic compounds as prmt5 inhibitors. | |
FI3221293T3 (en) | Ionizable cationic lipid for rna delivery | |
MX2022007130A (en) | Substituted piperazine derivatives useful as t cell activators. | |
NZ720174A (en) | Ionizable cationic lipid for rna delivery | |
MX2012009186A (en) | Substituted pyrrolidine-2-carboxamides. | |
MX2022007369A (en) | Substituted quinolinonyl piperazine compounds useful as t cell activators. | |
MX2020002825A (en) | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia. | |
CR20220251A (en) | New methylquinazolinone derivatives | |
MX2016004964A (en) | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof. | |
JO3811B1 (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors | |
MX2011008176A (en) | 3, 3' -spiroindolinone derivatives as anticancer agents. | |
TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
EA201991025A1 (en) | LIPOSOMAL DRUG FOR APPLICATION FOR TREATMENT OF MALIGNANT NORMAL EDUCATION | |
EP4001273A3 (en) | Aminopyrimidines as alk inhibitors | |
MA38865A1 (en) | Formulation comprising a lipid-lowering agent | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
WO2018201167A3 (en) | Propionic acid derivatives and methods of use thereof | |
MX2018011721A (en) | Griseofulvin compound. | |
MX2016005993A (en) | Biscationic and triscationic amphiles as antimicrobial agents. |